Author

J. Seow

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 6 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:host-pathogen & immune response· 7 Organism:human· 5 Assay:proteomics· 5 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Organism:mouse· 1 Assay:structural biology· 1

Frequent Co-Authors

K. J. Doores· 7 shared C. Graham· 5 shared I. Huettner· 3 shared M. H. Malim· 3 shared A. Rosa· 2 shared A. Waters· 2 shared C. Mant· 2 shared J. Fox· 2 shared

Activity by Year

2020-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersImmunology

K. J. Doores

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Broad and potent neutralizing mAbs are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection

J. Seow, Z. A. Shalim, C. Graham, S. Kimuda, A. Pillai, T. Lechmere, A. Kurshan, A. Khimji, L. Snell, G. Nebbia, C. Mant, A. Waters, J. Fox, M. H. Malim, K. J. Doores

The paper shows that vaccinated individuals develop broad neutralizing mAbs after Delta/BA.1 infection, but these mAbs are less effective against newer variants.

bioRxiv · Mar 30, 2023 · PreprintImmunology

ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants

J. Seow, C. Graham, S. R. Hallett, T. Lechmere, T. J. A. Maguire, I. Huettner, D. Cox, R. Roberts, A. Waters, C. C. Ward, C. Mant, M. J. Pitcher, J. Spencer, J. Fox, M. H. Malim, K. J. Doores

This study isolates monoclonal antibodies from a vaccinated individual and shows they neutralize multiple SARS-CoV-2 variants effectively.

bioRxiv · Sep 27, 2021Immunology

The legacy of maternal SARS-CoV-2 infection on the immunology of the neonate

S. Gee, M. Chandiramani, J. Seow, C. Modestini, A. Das, K. J. Doores, R. M. Tribe, D. L. Gibbons

This study examines the impact of maternal SARS-CoV-2 infection on neonatal immunology, finding increased pro-inflammatory cytokines and immune cell percentages in infants exposed in utero.

bioRxiv · May 27, 2021Immunology

ADNKA overcomes SARS-CoV2-mediated NK cell inhibition through non-spike antibodies

C. A. Fielding, P. Sabberwal, J. C. Williamson, E. J. Greenwood, E. Crozier, W. Zelek, J. Seow, C. Graham, I. Huettner, J. Edgeworth, B. P. Morgan, K. Ladell, M. Eberl, I. R. Humphreys, B. Merrick, , R. J. Stanton

This study identifies ADNKA as a mechanism by which SARS-CoV-2-infected cells evade NK cell inhibition, showing that non-spike antibodies drive sustained NK activation and cytokine production.

bioRxiv · Apr 6, 2021Immunology

Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike

C. Graham, J. Seow, I. Huettner, H. Khan, N. Kouphou, S. Acors, H. Winstone, S. Pickering, R. Pedro Galao, M. Jose Lista, J. M. Jimenez-Guardeno, A. G. Laing, Y. Wu, M. Joseph, L. Muir, , K. J. Doores

This study examines how mutations in the B.1.1.7 variant of SARS-CoV-2 affect neutralization by monoclonal antibodies targeting non-RBD epitopes.

bioRxiv · Feb 3, 2021 · PreprintImmunology

The impact of Spike mutations on SARS-CoV-2 neutralization

C. Rees-Spear, L. Muir, S. A. Griffith, J. Heaney, Y. Aldon, J. Snitselaar, P. Thomas, C. Graham, J. Seow, N. Lee, A. Rosa, C. Roustan, C. F. Houlihan, R. W. Sanders, R. K. Gupta, , L. E. McCoy

This study evaluates how Spike mutations in SARS-CoV-2 variants affect neutralization by monoclonal and polyclonal antibodies, showing reduced activity in some cases.

bioRxiv · Jan 15, 2021 · PreprintImmunology

Molecular rationale for hantavirus neutralization by a reservoir host-derived monoclonal antibody

I. Rissanen, R. Stass, S. A. Krumm, J. Seow, R. J. G. Hulswit, G. C. Paesen, J. Hepojoki, O. Vapalahti, A. Lundkvist, O. Reynard, V. Volchkov, K. J. Doores, J. T. Huiskonen, T. A. Bowden

This study investigates how a monoclonal antibody neutralizes hantaviruses by targeting the glycoprotein lattice, revealing structural insights into antibody binding and its impact on viral entry.

bioRxiv · Apr 17, 2020Microbiology